ArticlePulmonary therapy2026
Modeling the Potential Public Health Impact of Updated COVID-19 Vaccination Strategies in Singapore: Epidemiological Data Update.
Article in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study estimated the potential public health impact of alternative COVID-19 vaccination strategies in Singapore.
methodsThe outcomes of alternative vaccination strategies using a Pfizer-BioNTech COVID-19 vaccine updated to the latest circulating strain were estimated using a combined decision tree-Markov cohort model. The model was previously used to estimate the impact of vaccination based on epidemiological data from 2021/22 and vaccine coverage data from 2022/23. It has now been updated with epidemiology data from 2023/24 and an assumed vaccine coverage of 20%. Age-specific inputs were derived from local epidemiological data and published sources. The model projected health outcomes (cases, hospitalizations, and deaths) and economic outcomes (direct medical costs and productivity losses) across different age and risk subgroups.
resultsVaccinating individuals aged 60 and above, as well as individuals aged 6 months to 59 years with comorbidities, making them at high risk for severe COVID-19 outcomes, with a vaccine coverage of 20%, is projected to result in 14,099 fewer infections, 2668 fewer hospitalizations, and 21 fewer deaths in 1 year. This leads to a total estimated savings of SGD 21.3 million in direct medical costs and SGD 24.8 million in indirect costs. Increasing coverage to 50% has the potential to further increase deaths, hospitalizations, infections, and costs averted by 150%.
conclusionsAlthough vaccination has a smaller impact on public health compared to the previous evaluation because of the updated epidemiology and lower estimated coverage, an updated vaccine can still have a public health and economic impact in Singapore.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.